Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective
Open Access
- 18 March 2025
- journal article
- review article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (4) , 671-733
Abstract
Immunocompromised patients are disproportionately impacted by severe disease, hospitalization, and mortality associated with coronavirus disease 2019 (COVID-19). To optimize the management of these patients in clinical practice, we convened an expert panel to review current evidence on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine responses and severe COVID-19 in immunocompromised populations. We identified four main immunocompromised groups—solid organ transplant recipients, patients receiving allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T cell therapy, patients treated for hematologic malignancies, and patients treated for inflammatory diseases—who mount suboptimal humoral responses to SARS-CoV-2 vaccination and are at increased risk of severe COVID-19-related outcomes. A wide range of risk factors were associated with reduced vaccine responses and/or poor outcomes, most commonly older age, comorbidities, and the type and number of immunosuppressive therapies. We believe that early identification and close monitoring of these at-risk patients, plus regular booster vaccinations, prophylactic monoclonal antibody therapy, non-pharmacologic prevention measures, prompt antiviral treatment, and other risk mitigation strategies, are critical to protect against SARS-CoV-2 infection and severe COVID-19.Keywords
This publication has 79 references indexed in Scilit:
- Severe COVID-19 in Vaccinated Adults With Hematologic Cancers in the Veterans Health AdministrationJAMA Network Open, 2024
- COVID‐19 in cancer patients: The impact of vaccination on outcomes early in the pandemicCancer Medicine, 2023
- COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive TherapyJAMA Network Open, 2023
- Torque teno virus viral load predicts SARS‐CoV‐2 vaccine response in kidney transplant recipientsJournal of Medical Virology, 2023
- Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant RecipientsAdvances in Therapy, 2023
- Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseasesClinical Rheumatology, 2023
- Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs HospitalsJAMA Network Open, 2022
- Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United StatesAdvances in Therapy, 2022
- Rituximab Impairs B Cell Response But Not T Cell Response to COVID‐19 Vaccine in Autoimmune DiseasesArthritis & Rheumatology, 2022
- SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observationsHematological Oncology, 2021